NeuroMetrix (NURO) 10-Q 22 Apr 21 2021 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2021	Apr. 21, 2021
Document Information [Line Items]
Substantial Doubt about Going Concern, within One Year [true false]	true
Entity Central Index Key	0001289850
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding		3,803,195
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Type	10-Q
Entity Current Reporting Status	Yes
Entity Small Business	true
Entity Interactive Data Current	Yes
Security Exchange Name	NASDAQ
Trading Symbol	NURO
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2021
Document Transition Report	false
Entity File Number	001-33351
Entity Registrant Name	NEUROMETRIX, INC.
Entity Incorporation, State or Country Code	DE
Entity Address, Postal Zip Code	01801
Local Phone Number	890-9989
Entity Filer Category	Non-accelerated Filer
Entity Tax Identification Number	04-3308180
Entity Address, Address Line One	4B Gill Street
Entity Address, City or Town	Woburn
Entity Address, State or Province	MA
City Area Code	781
Title of 12(b) Security	Common Stock, $0.0001 par value per share

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 5,145,167	$ 5,226,213
Accounts receivable, net	477,689	334,297
Inventories	979,626	1,051,282
Prepaid expenses and other current assets	362,921	478,074
Total current assets	6,965,403	7,089,866
Fixed assets, net	182,765	183,494
Operating Lease, Right-of-Use Asset	544,420	692,692
Other long-term assets	28,284	28,523
Total assets	7,720,872	7,994,575
Current liabilities:
Accounts payable	381,248	142,316
Accrued expenses and compensation	605,489	998,442
Accrued Sales Return provisions	535,000	545,000
Operating Lease, Liability, Current	566,256	599,632
Total current liabilities	2,087,993	2,285,390
Operating Lease, Liability, Noncurrent	371,827	461,410
Total liabilities	2,459,820	2,746,800
Commitments and contingencies
Stockholders’ equity:
Common Stock, Value, Issued	380	379
Additional paid-in capital	202,202,254	202,129,195
Accumulated deficit	(196,941,583)	(196,881,800)
Total stockholders’ equity	5,261,052	5,247,775
Total liabilities and stockholders’ equity	$ 7,720,872	$ 7,994,575
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	25,000,000	25,000,000
Common Stock, Shares, Issued	3,796,147	3,793,739
Common Stock, Shares, Outstanding	3,796,147	3,793,739
Convertible preferred stock
Stockholders’ equity:
Preferred stock	$ 1	$ 1
Total stockholders’ equity	1	1
Preferred Non-Convertible Stock
Stockholders’ equity:
Preferred stock	$ 0	$ 0

Statements of Operations (Unaud

Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue from Contract with Customer, Including Assessed Tax	$ 2,155,472	$ 2,172,036
Other Nonoperating Income	412	498
Net loss	(59,783)	(657,371)
Loss from operations	$ (60,195)	$ (657,869)
Net income (loss) applicable to common stockholders:
Earnings Per Share, Basic and Diluted	$ (0.02)	$ (0.45)
Weighted Average Number of Shares Outstanding, Basic	3,796,120	1,457,224
Operating expenses:
Research and development	$ 233,277	$ 533,620
Sales and marketing	393,825	424,349
General and administrative	1,012,276	1,251,746
Total operating expenses	1,639,378	2,209,715
Gross profit	1,579,183	1,551,846
Cost of revenues	$ 576,289	$ 620,190

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Statement of Cash Flows [Abstract]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ (59,783)	$ (657,371)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	22,182	23,407
Stock-based compensation	68,863	144,047
CompensationObligationSettlement	0	43,751
IdleFacilityImpairmentCharge	126,748	87,000
Changes in operating assets and liabilities:
Accounts receivable	(143,392)	(87,157)
Inventories	71,656	10,154
Increase (Decrease) In Collaboration Receivable	0	7,678
Prepaid expenses and other current and long-term assets	(16,043)	312,550
Accounts payable	238,932	(102,465)
Accrued expenses and compensation	(332,953)	(458,772)
Increase (Decrease) in Accrued Product Returns	(10,000)	(86,000)
Net Cash Provided by (Used in) Operating Activities	(33,790)	(763,178)
Cash flows from investing activities:
Purchases of fixed assets	(21,453)	0
Net Cash Provided by (Used in) Investing Activities	(21,453)	0
Cash flows from financing activities:
Net proceeds from issuance of stock and warrants	4,197	453,457
Payments of Stock Issuance Costs	(30,000)	0
Net Cash Provided by (Used in) Financing Activities	(25,803)	453,457
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	(81,046)	(309,721)
Cash and cash equivalents, end of period	5,145,167
Supplemental disclosure of cash flow information:
Stock Issuance Settle Incentive Compensation Obligation	0	43,751
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	$ 5,145,167	$ 2,816,485

Equity Rollforward Statement

Equity Rollforward Statement - USD ($)	Total	Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Stockholders' Equity Attributable to Parent	$ 2,530,234	$ 1	$ 140	$ 197,319,698	$ (194,789,605)
Shares, Outstanding		200	1,400,674
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	144,047			144,047
Stock Issued During Period, Shares, New Issues			256,078
Stock Issued During Period, Value, New Issues	453,457		$ 25	453,432
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture			31,000
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	43,751		$ 3	43,748
Net Income (Loss) Attributable to Parent	(657,371)				(657,371)
Stockholders' Equity Attributable to Parent	2,514,118	$ 1	$ 168	197,960,925	(195,446,976)
Shares, Outstanding		200	1,687,752
Stockholders' Equity Attributable to Parent	5,247,775	$ 1	$ 379	202,129,195	(196,881,800)
Shares, Outstanding		200	3,793,739
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	68,863			68,863
Stock Issued During Period, Shares, Employee Stock Purchase Plans			2,408
Stock Issued During Period, Value, Employee Stock Purchase Plan	4,197		$ 1	4,196
Net Income (Loss) Attributable to Parent	(59,783)				(59,783)
Stockholders' Equity Attributable to Parent	$ 5,261,052	$ 1	$ 380	$ 202,202,254	$ (196,941,583)
Shares, Outstanding		200	3,796,147

Business and Basis of Presentat

Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Business and Basis of Presentation	Business and Basis of Presentation Our Business-An Overview NeuroMetrix, Inc. (the Company) develops and commercializes health care products that utilize non-invasive neurostimulation. Revenues are derived from the sale of medical devices and after-market consumable products and accessories. The Company’s products are sold in the United States and select overseas markets. They are cleared by the U.S. Food and Drug Administration (FDA) and regulators in foreign jurisdictions where appropriate. The Company has two primary products. DPNCheck® is a point-of-care test for diabetic peripheral neuropathy, which is the most common long-term complication of Type 2 diabetes. Quell is an app-enabled, over-the-counter wearable device for chronic pain. The accompanying financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company has reported recurring losses from operations and negative cash flows from operating activities. At March 31, 2021, the Company had an accumulated deficit of $196.9 million. These factors raise substantial doubt about the Company’s ability to continue as a going concern for the one-year period from the date of issuance of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company held cash and cash equivalents of $5.1 million as of March 31, 2021. The Company believes that these resources and the cash to be generated from future product sales will be sufficient to meet its projected operating requirements through the first quarter of 2022. Accordingly, the Company may need to raise additional funds to support its operating and capital needs in the second quarter of 2022 and beyond. The Company continues to face significant challenges and uncertainties and, as a result, the Company’s available capital resources may be consumed more rapidly than currently expected due to (a) decreases in sales of the Company’s products related to the COVID-19 pandemic and other factors, and the uncertainty of future revenues from new products; (b) the effect of the COVID-19 pandemic on the Company's ability to obtain parts and materials from suppliers while continuing to staff critical production and fulfillment functions; (c) changes the Company may make to the business that affect ongoing operating expenses; (d) changes the Company may make in its business strategy; (e) regulatory developments affecting the Company’s existing products; (f) changes the Company may make in its research and development spending plans; and (g) other items affecting the Company’s forecasted level of expenditures and use of cash resources. The Company may attempt to obtain additional funding from public or private financing, collaborative arrangements with strategic partners, divestiture of assets or through credit lines or other debt financing sources to increase the funds available to fund operations. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity or debt securities to raise additional funds, its existing stockholders may experience dilution, and the new equity or debt securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or to proprietary technologies, or grant licenses on terms that are not favorable to the Company. Without additional funds, the Company may be forced to delay, scale back or eliminate some of its sales and marketing efforts, research and development activities, or other operations and potentially delay product development in an effort to provide sufficient funds to continue its operations. If any of these events occurs, the Company’s ability to achieve its development and commercialization goals would be adversely affected. Unaudited Interim Financial Statements The accompanying unaudited balance sheet as of March 31, 2021, unaudited statements of operations, changes in stockholders' equity for the quarters ended March 31, 2021 and 2020 and cash flows for the quarters ended March 31, 2021 and 2020 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying balance sheet as of December 31, 2020 has been derived from audited financial statements prepared at that date but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, the financial statements include all normal and recurring adjustments considered necessary for a fair presentation of the Company’s financial position and operating results. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, or the SEC, on January 29, 2021 (File No. 001-33351). Revenues Revenues include product sales, net of estimated returns. Revenue is measured as the amount of consideration the Company expects to receive in exchange for product transferred. Revenue is recognized when contractual performance obligations have been satisfied and control of the product has been transferred to the customer. In most cases, the Company has a single product delivery performance obligation. Accrued product returns are estimated based on historical data and evaluation of current information. Accounts receivable are recorded at the amount the Company expects to collect, net of the allowance for doubtful accounts receivable. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses based on customer past payment history, product usage activity, and recent communications with the customer. Individual customer balances which are over 90 days past due are reviewed individually for collectability and written-off when recovery is not probable. Allowance for doubtful accounts was $25,000 as of March 31, 2021 and December 31, 2020. One customer accounted for 36% of total revenues in the quarter ended March 31, 2021 and two customers accounted for 36% of total revenues in the quarter ended March 31, 2020. One customer accounted for 33% and two customers accounted for 50% of accounts receivable as of March 31, 2021 and December 31, 2020, respectively. Stock-based Compensation Total compensation cost related to non-vested awards not yet recognized at March 31, 2021 was $170,683. The total compensation costs are expected to be recognized over a weighted-average period of 1.2 years. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.

Comprehensive Loss

Comprehensive Loss	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Comprehensive Loss	Comprehensive Loss For the quarters ended March 31, 2021 and 2020, the Company had no components of other comprehensive loss other than net loss itself.

Net Loss Per Common Share

Net Loss Per Common Share	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Net Loss Per Common Share	3. Net Loss Per Common Share Basic and dilutive net loss per common share were as follows: Quarters Ended March 31, 2021 2020 Net loss applicable to common stockholders $ (59,783) $ (657,371) Weighted average number of common shares outstanding, basic 3,796,120 1,457,224 Dilutive convertible preferred stock — — Weighted average number of common shares outstanding, dilutive 3,796,120 1,457,224 Net loss per common share applicable to common stockholders, basic and diluted $ (0.02) $ (0.45) Shares underlying the following potentially dilutive weighted average number of common stock equivalents were excluded from the calculation of diluted net loss per common share because their effect was anti-dilutive for each of the periods presented: Quarters Ended March 31, 2021 2020 Options 368,510 164,091 Warrants — 42,086 Convertible preferred stock 62 62 Total 368,572 206,239
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Quarters Ended March 31, 2021 2020 Net loss applicable to common stockholders $ (59,783) $ (657,371) Weighted average number of common shares outstanding, basic 3,796,120 1,457,224 Dilutive convertible preferred stock — — Weighted average number of common shares outstanding, dilutive 3,796,120 1,457,224 Net loss per common share applicable to common stockholders, basic and diluted $ (0.02) $ (0.45)

Inventories

Inventories	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: March 31, 2021 December 31, 2020 Purchased components $ 709,841 $ 716,848 Finished goods 269,785 334,434 $ 979,626 $ 1,051,282

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2021
Payables and Accruals [Abstract]
Accrued Expenses	Accrued Expenses and Compensation Accrued expenses and compensation consist of the following: March 31, 2021 December 31, 2020 Professional services $ 199,000 $ 343,000 Compensation 186,614 49,837 Advertising and promotion 1,000 31,000 Warranty 42,700 49,600 Technology fees — 450,000 Other 176,175 75,005 $ 605,489 $ 998,442

Leases Leases (Notes)

Leases Leases (Notes)	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Lessee, Operating Leases [Text Block]	The Company's lease on its Woburn, Massachusetts corporate office and manufacturing facilities (the “Woburn Lease”) extends through September 2025 with a monthly base rent of $13,846 and a 5-year extension option. The Company's lease on its former corporate office in Waltham, Massachusetts (the "Waltham Lease") extends through February 2022 with an average monthly base rent of $41,074 and a 5-year extension option. A letter of credit in the amount of $226,731, secured by the Company's cash balances, was issued by a bank in favor on the Waltham Lease landlord. While the Company continues to actively seek a sublet for the Waltham Lease under difficult market conditions, the Company recorded an impairment charge for idle facility costs of $126,748 in the quarter ended March 31, 2021 to reduce the remaining value of its right-to-use asset in the Waltham facility to zero and $60,000 in accrued expense to provide for estimated costs of returning the property to the lessor. Future minimum lease payments under non-cancellable operating leases as of March 31, 2021 are as follows: 2021 $ 491,369 2022 247,347 2023 165,785 2024 165,785 2025 117,431 Total minimum lease payments $ 1,187,717 Weighted-average discount rate, 14.7% $ 249,634 Lease obligation, current portion 566,256 Lease obligation, net of current portion 371,827 $ 1,187,717 Total recorded rent expense was $166,904, for the quarters ended March 31, 2021 and 2020. The Company records rent expense on its facility leases on a straight-line basis over the lease term. Weighted average remaining operating lease term was 2.9 years as of March 31, 2021.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis for the periods presented and indicates the fair value hierarchy of the valuation techniques it utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates, and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. All Company assets and liabilities measured at fair value utilize Level 1 inputs. Fair Value Measurements at March 31, 2021 Using March 31, 2021 Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 2,302,891 $ 2,302,891 $ — $ — Total $ 2,302,891 $ 2,302,891 $ — $ — Fair Value Measurements at December 31, 2020 Using December 31, 2020 Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 2,374,216 $ 2,374,216 $ — $ — Total $ 2,374,216 $ 2,374,216 $ — $ —

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Preferred stock and convertible preferred stock consist of the following: March 31, 2021 December 31, 2020 Preferred stock, $0.001 par value; 5,000,000 shares authorized at March 31, 2021 and December 31, 2020; no shares issued and outstanding at March 31, 2021 and December 31, 2020 $ — $ — Series B convertible preferred stock, $0.001 par value; 147,000 shares designated at March 31, 2021 and December 31, 2020; 200 shares issued and outstanding at March 31, 2021 and December 31, 2020 $ 1 $ 1 Series D convertible preferred stock, $0.001 par value; 21,300 shares designated at March 31, 2021 and December 31, 2020; no shares issued and outstanding at March 31, 2021 and December 31, 2020 $ — $ — Series E convertible preferred stock, $0.001 par value; 7,000 shares designated at March 31, 2021 and December 31, 2020; no shares issued and outstanding at March 31, 2021 and December 31, 2020 $ — $ — Series F convertible preferred stock, $0.001 par value; 10,621 shares designated at March 31, 2021 and December 31, 2020; no shares issued and outstanding at March 31, 2021 and December 31, 2020 $ — $ — 2021 equity activity In January 2021, the Company issued 2,408 shares of fully vested common stock with a value of $4,197 pursuant to the Company's 2010 Employee Stock Purchase Plan. 2020 equity activity In February 2020, the Company entered into an At Market Issuance Sales Agreement (the "Agreement") with respect to an at-the-market offering program ("ATM program"), under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the "Common Stock"), subject to the regulatory limitations imposed by the Securities and Exchange Commission (the "Placement Shares"). The issuance and sale of the Placement Shares by the Company under the Agreement will be made pursuant to the Company's effective "shelf" registration statement on Form S-3. During the three months ended March 31, 2020, 256,078 shares of common stock were issued pursuant to the Agreement for proceeds of $453,457. During 2020, 2,348,619 shares of common stock were issued pursuant to the Agreement for net proceeds of $4,143,431.

Reverse Stock Split

Reverse Stock Split	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Reverse Stock Split	Stockholders’ Equity Preferred stock and convertible preferred stock consist of the following: March 31, 2021 December 31, 2020 Preferred stock, $0.001 par value; 5,000,000 shares authorized at March 31, 2021 and December 31, 2020; no shares issued and outstanding at March 31, 2021 and December 31, 2020 $ — $ — Series B convertible preferred stock, $0.001 par value; 147,000 shares designated at March 31, 2021 and December 31, 2020; 200 shares issued and outstanding at March 31, 2021 and December 31, 2020 $ 1 $ 1 Series D convertible preferred stock, $0.001 par value; 21,300 shares designated at March 31, 2021 and December 31, 2020; no shares issued and outstanding at March 31, 2021 and December 31, 2020 $ — $ — Series E convertible preferred stock, $0.001 par value; 7,000 shares designated at March 31, 2021 and December 31, 2020; no shares issued and outstanding at March 31, 2021 and December 31, 2020 $ — $ — Series F convertible preferred stock, $0.001 par value; 10,621 shares designated at March 31, 2021 and December 31, 2020; no shares issued and outstanding at March 31, 2021 and December 31, 2020 $ — $ — 2021 equity activity In January 2021, the Company issued 2,408 shares of fully vested common stock with a value of $4,197 pursuant to the Company's 2010 Employee Stock Purchase Plan. 2020 equity activity In February 2020, the Company entered into an At Market Issuance Sales Agreement (the "Agreement") with respect to an at-the-market offering program ("ATM program"), under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the "Common Stock"), subject to the regulatory limitations imposed by the Securities and Exchange Commission (the "Placement Shares"). The issuance and sale of the Placement Shares by the Company under the Agreement will be made pursuant to the Company's effective "shelf" registration statement on Form S-3. During the three months ended March 31, 2020, 256,078 shares of common stock were issued pursuant to the Agreement for proceeds of $453,457. During 2020, 2,348,619 shares of common stock were issued pursuant to the Agreement for net proceeds of $4,143,431.

Business and Basis of Present_2

Business and Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Share-based Payment Arrangement [Policy Text Block]	Stock-based Compensation Total compensation cost related to non-vested awards not yet recognized at March 31, 2021 was $170,683. The total compensation costs are expected to be recognized over a weighted-average period of 1.2 years.
Unaudited Interim Financial Statements	Unaudited Interim Financial Statements The accompanying unaudited balance sheet as of March 31, 2021, unaudited statements of operations, changes in stockholders' equity for the quarters ended March 31, 2021 and 2020 and cash flows for the quarters ended March 31, 2021 and 2020 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying balance sheet as of December 31, 2020 has been derived from audited financial statements prepared at that date but does not include all disclosures required by accounting principles generally accepted in the United States of America. In the opinion of management, the financial statements include all normal and recurring adjustments considered necessary for a fair presentation of the Company’s financial position and operating results. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021 or any other period. These financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, or the SEC, on January 29, 2021 (File No. 001-33351).
Revenues	Revenues Revenues include product sales, net of estimated returns. Revenue is measured as the amount of consideration the Company expects to receive in exchange for product transferred. Revenue is recognized when contractual performance obligations have been satisfied and control of the product has been transferred to the customer. In most cases, the Company has a single product delivery performance obligation. Accrued product returns are estimated based on historical data and evaluation of current information. Accounts receivable are recorded at the amount the Company expects to collect, net of the allowance for doubtful accounts receivable. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses based on customer past payment history, product usage activity, and recent communications with the customer. Individual customer balances which are over 90 days past due are reviewed individually for collectability and written-off when recovery is not probable. Allowance for doubtful accounts was $25,000 as of March 31, 2021 and December 31, 2020. One customer accounted for 36% of total revenues in the quarter ended March 31, 2021 and two customers accounted for 36% of total revenues in the quarter ended March 31, 2020. One customer accounted for 33% and two customers accounted for 50% of accounts receivable as of March 31, 2021 and December 31, 2020, respectively.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2021
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Quarters Ended March 31, 2021 2020 Net loss applicable to common stockholders $ (59,783) $ (657,371) Weighted average number of common shares outstanding, basic 3,796,120 1,457,224 Dilutive convertible preferred stock — — Weighted average number of common shares outstanding, dilutive 3,796,120 1,457,224 Net loss per common share applicable to common stockholders, basic and diluted $ (0.02) $ (0.45)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Quarters Ended March 31, 2021 2020 Options 368,510 164,091 Warrants — 42,086 Convertible preferred stock 62 62 Total 368,572 206,239

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consist of the following: March 31, 2021 December 31, 2020 Purchased components $ 709,841 $ 716,848 Finished goods 269,785 334,434 $ 979,626 $ 1,051,282

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2021
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses and compensation consist of the following: March 31, 2021 December 31, 2020 Professional services $ 199,000 $ 343,000 Compensation 186,614 49,837 Advertising and promotion 1,000 31,000 Warranty 42,700 49,600 Technology fees — 450,000 Other 176,175 75,005 $ 605,489 $ 998,442

Leases Leases (Tables)

Leases Leases (Tables)	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2021 $ 491,369 2022 247,347 2023 165,785 2024 165,785 2025 117,431 Total minimum lease payments $ 1,187,717 Weighted-average discount rate, 14.7% $ 249,634 Lease obligation, current portion 566,256 Lease obligation, net of current portion 371,827 $ 1,187,717

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	Fair Value Measurements at March 31, 2021 Using March 31, 2021 Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 2,302,891 $ 2,302,891 $ — $ — Total $ 2,302,891 $ 2,302,891 $ — $ — Fair Value Measurements at December 31, 2020 Using December 31, 2020 Quoted Prices in Significant Other Significant Assets: Cash equivalents $ 2,374,216 $ 2,374,216 $ — $ — Total $ 2,374,216 $ 2,374,216 $ — $ —

Statement of Shareholders' Equi

Statement of Shareholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Schedule of Stock by Class [Table Text Block]	Preferred stock and convertible preferred stock consist of the following: March 31, 2021 December 31, 2020 Preferred stock, $0.001 par value; 5,000,000 shares authorized at March 31, 2021 and December 31, 2020; no shares issued and outstanding at March 31, 2021 and December 31, 2020 $ — $ — Series B convertible preferred stock, $0.001 par value; 147,000 shares designated at March 31, 2021 and December 31, 2020; 200 shares issued and outstanding at March 31, 2021 and December 31, 2020 $ 1 $ 1 Series D convertible preferred stock, $0.001 par value; 21,300 shares designated at March 31, 2021 and December 31, 2020; no shares issued and outstanding at March 31, 2021 and December 31, 2020 $ — $ — Series E convertible preferred stock, $0.001 par value; 7,000 shares designated at March 31, 2021 and December 31, 2020; no shares issued and outstanding at March 31, 2021 and December 31, 2020 $ — $ — Series F convertible preferred stock, $0.001 par value; 10,621 shares designated at March 31, 2021 and December 31, 2020; no shares issued and outstanding at March 31, 2021 and December 31, 2020 $ — $ —

Business and Basis of Present_3

Business and Basis of Presentation (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Organization And Basis Of Presentation [Line Items]
Accounts receivable, net	$ 477,689		$ 334,297
Net proceeds from issuance of stock and warrants	4,197	$ 453,457
Accumulated deficit	196,941,583		196,881,800
Cash and cash equivalents	5,145,167		5,226,213
Prepaid expenses and other current assets	(362,921)		(478,074)
Assets, Current	(6,965,403)		(7,089,866)
Accrued Sales Return provisions	535,000		545,000
Liabilities, Current	(2,087,993)		(2,285,390)
Operating Lease, Liability, Noncurrent	(371,827)		(461,410)
Stockholders' Equity Attributable to Parent	5,261,052	2,514,118	5,247,775	$ 2,530,234
Cost of revenues	576,289	620,190
Gross Profit	1,579,183	1,551,846
Compensation cost not yet recognized	$ 170,683
Compensation cost not yet recognized, period for recognition	1 year 2 months 12 days
Operating Lease, Right-of-Use Asset	$ (544,420)		(692,692)
Other long-term assets	(28,284)		(28,523)
Assets	(7,720,872)		(7,994,575)
Accrued Liabilities, Current	(605,489)		(998,442)
Liabilities	(2,459,820)		(2,746,800)
Allowance for doubtful accounts	25,000		$ 25,000
Other Comprehensive Income (Loss), Net of Tax	$ 0	$ 0
One Customer | Revenue | Customer Concentration Risk
Organization And Basis Of Presentation [Line Items]
Concentration risk, percentage	36.00%
One Customer | Accounts Receivable | Customer Concentration Risk
Organization And Basis Of Presentation [Line Items]
Concentration risk, percentage	33.00%
Three Customers [Member] | Accounts Receivable | Customer Concentration Risk
Organization And Basis Of Presentation [Line Items]
Concentration risk, percentage			50.00%
Two Customers | Revenue | Customer Concentration Risk
Organization And Basis Of Presentation [Line Items]
Concentration risk, percentage		36.00%

Net Loss Per Common Share - Sch

Net Loss Per Common Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	368,572	206,239
Convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	62	62
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	368,510	164,091
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total antidilutive securities excluded from the computation of earnings per share (in shares)	0	42,086

Net Loss Per Common Share Sched

Net Loss Per Common Share Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Earnings Per Share [Abstract]
Net Income (Loss) Attributable to Parent	$ (59,783)	$ (657,371)
Weighted Average Number of Shares Outstanding, Basic	3,796,120	1,457,224
Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock	0	0
Weighted Average Number of Shares Outstanding, Diluted	3,796,120	1,457,224
Earnings Per Share, Basic and Diluted	$ (0.02)	$ (0.45)

Inventories (Detail)

Inventories (Detail) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Inventory [Line Items]
Purchased components	$ 709,841	$ 716,848
Finished goods	269,785	334,434
Inventories	$ 979,626	$ 1,051,282

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Sales return allowance	$ 535,000	$ 545,000
Technology fees	0	450,000
Professional services	199,000	343,000
Warranty reserve	42,700	49,600
Accrued Advertising	1,000	31,000
Accrued Salaries	186,614	49,837
Other	176,175	75,005
Accrued expenses	605,489	$ 998,442
Accrued Technology Fees Write Off	$ 450,000

Leases Leases (Details)

Leases Leases (Details) - USD ($)	Jun. 01, 2018	Feb. 20, 2015	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Operating Leased Assets [Line Items]
Operating Lease, Weighted Average Discount Rate, Percent			14.70%
Operating Lease, Weighted Average Remaining Lease Term			2 years 10 months 24 days
IdleFacilityImpairmentCharge			$ 126,748	$ 87,000
Operating Lease, Expense			166,904	$ 166,904
Operating Lease, Right-of-Use Asset			544,420		$ 692,692
Lessee, Operating Lease, Liability, to be Paid, Year One			491,369
Lessee, Operating Lease, Liability, to be Paid, Year Two			247,347
Lessee, Operating Lease, Liability, to be Paid, Year Three			165,785
Lessee, Operating Lease, Liability, to be Paid, Year Four			165,785
Lessee, Operating Lease, Liability, to be Paid, after Year Five			117,431
Lessee, Operating Lease, Liability, to be Paid			1,187,717
Operating Lease Discount			249,634
Operating Lease, Liability, Current			566,256		599,632
Operating Lease, Liability, Noncurrent			371,827		$ 461,410
Woburn Lease [Member]
Operating Leased Assets [Line Items]
Lessee, Operating Lease, Renewal Term	5 years
Woburn Lease [Member] | MonthlyRent [Member]
Operating Leased Assets [Line Items]
Operating Lease, Payments	$ 13,846
Waltham Lease [Member]
Operating Leased Assets [Line Items]
Lessee, Operating Lease, Renewal Term		5 years
Credit facility limit restricted to support letter of credit			226,731
Operating Lease, Right-of-Use Asset			0
Accrued Liabilities			60,000
Waltham Lease [Member] | Idle Facility Impairment [Member]
Operating Leased Assets [Line Items]
Restructuring Charges			$ 126,748
Waltham Lease [Member] | MonthlyRent [Member]
Operating Leased Assets [Line Items]
Operating Lease, Payments		$ 41,074

Restructuring And Related Activ

Restructuring And Related Activities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Restructuring Cost and Reserve [Line Items]
IdleFacilityImpairmentCharge	$ 126,748	$ 87,000

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Assets
Cash equivalents	$ 2,302,891	$ 2,374,216
Assets, Fair Value Disclosure	2,302,891	2,374,216
Level 1
Assets
Cash equivalents	2,302,891	2,374,216
Assets, Fair Value Disclosure	2,302,891	2,374,216
Level 2
Assets
Cash equivalents	0	0
Assets, Fair Value Disclosure	0	0
Level 3
Assets
Cash equivalents	0	0
Assets, Fair Value Disclosure	$ 0	$ 0

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	1 Months Ended		3 Months Ended		12 Months Ended
	Jan. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Mar. 11, 2020	Feb. 29, 2020
Class of Stock [Line Items]
Stock Issued During Period, Value, Employee Stock Purchase Plan			$ 4,197
Net proceeds from issuance of stock and warrants			$ 4,197	$ 453,457
Common stock, par value (in dollars per share)			$ 0.0001		$ 0.0001
Compensation cost not yet recognized			$ 170,683
Compensation cost not yet recognized, period for recognition			1 year 2 months 12 days
Series D Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares outstanding (in shares)			0		0
Series E Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, shares outstanding (in shares)			0		0
Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Employee Stock Purchase Plans	2,408		2,408
Stock Issued During Period, Value, Employee Stock Purchase Plan	$ 4,197		$ 1
Stock Issued During Period, Shares, New Issues				256,078
Separation Agreement [Member] | Common Stock [Member]
Class of Stock [Line Items]
Stock Price (in dollars per share)						$ 1.41
Common Stock, Value, Issued		$ 43,751
Stock Issued During Period, Shares, Other		31,000
At The Market Offering Program [Member]
Class of Stock [Line Items]
Common stock, par value (in dollars per share)							$ 0.0001
Stock Issued During Period, Shares, New Issues			256,078		2,348,619
Proceeds from Issuance of Common Stock			$ 453,457		$ 4,143,431

Preferred Stock and Convertible

Preferred Stock and Convertible Preferred Stock (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Preferred Non-Convertible Stock
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Value of preferred stock issued	$ 0	$ 0
Preferred stock, shares outstanding (in shares)	0	0
Series B Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares issued (in shares)	200	200
Value of preferred stock issued	$ 1	$ 1
Preferred stock, shares designated (in shares)	147,000	147,000
Preferred stock, shares outstanding (in shares)	200	200
Series F Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares issued (in shares)	0	0
Value of preferred stock issued	$ 0	$ 0
Preferred stock, shares designated (in shares)	10,621	10,621
Preferred stock, shares outstanding (in shares)	0	0
Series D Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares issued (in shares)	0	0
Value of preferred stock issued	$ 0	$ 0
Preferred stock, shares designated (in shares)	21,300	21,300
Preferred stock, shares outstanding (in shares)	0	0
Series E Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares issued (in shares)	0	0
Value of preferred stock issued	$ 0	$ 0
Preferred stock, shares designated (in shares)	7,000	7,000
Preferred stock, shares outstanding (in shares)	0	0

Reverse Stock Split (Details)

Reverse Stock Split (Details) - shares	Mar. 31, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Shares outstanding (in shares)	3,796,147	3,793,739

Subsequent Event Subsequent Eve

Subsequent Event Subsequent Events (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Subsequent Event [Line Items]
Common Stock, Shares, Issued	3,796,147	3,793,739
At The Market Offering Program [Member]
Subsequent Event [Line Items]
Proceeds from Issuance of Common Stock	$ 453,457	$ 4,143,431

Uncategorized Items - nuro-2021

Label	Element	Value
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	$ 3,126,206
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	$ 5,226,213